Eloxx Pharmaceuticals Statistics
Want to see ELOX full AI Analyst Report?
Eloxx Pharmaceuticals (ELOX) Stock Statistics & Valuation Metrics
Total Valuation
Eloxx Pharmaceuticals has a market cap or net worth of $50.21M. The enterprise value is $32.27M.
- Market Cap
- $50.21M
- Enterprise Value
- $32.27M
Share Statistics
Eloxx Pharmaceuticals has 4,036,459 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,036,459
- Owned by Insiders
- 51.50%
- Owned by Institutions
- 3.92%
Financial Efficiency
Eloxx Pharmaceuticals’s return on equity (ROE) is 0.50 and return on invested capital (ROIC) is 59.03%.
- Return on Equity (ROE)
- 0.50
- Return on Assets (ROA)
- -1.14
- Return on Invested Capital (ROIC)
- 59.03%
- Return on Capital Employed (ROCE)
- 0.54
- Revenue Per Employee
- 0
- Profits Per Employee
- -599.50K
- Employee Count
- 10
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Eloxx Pharmaceuticals is -8.49. Eloxx Pharmaceuticals’s PEG ratio is -0.10.
- PE Ratio
- -8.49
- PS Ratio
- 0.00
- PB Ratio
- 1.89
- Price to FCF
- -4.33
- Price to Operating Cash Flow
- -8.55
- PEG Ratio
- -0.10
Income Statement
In the last 12 months, Eloxx Pharmaceuticals had revenue of 0 and earned -6.00M in profits. Earnings per share was -5.34.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -6.44M
- Pretax Income
- -6.00M
- Net Income
- -6.00M
- EBITDA
- -4.95M
- Earnings Per Share (EPS)
- -5.34
Cash Flow
In the last 12 months, operating cash flow was -10.24M and capital expenditures 0, giving a free cash flow of -10.24M billion.
- Operating Cash Flow
- -10.24M
- Free Cash Flow
- -10.24M
- Free Cash Flow per Share
- -1.51
Dividends & Yields
Eloxx Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.89%
- Earnings Yield
- -9.34%
Stock Price Statistics
- Beta
- -2604.49
- 52-Week Price Change
- 56.34%
- 50-Day Moving Average
- 14.72
- 200-Day Moving Average
- 10.38
- Relative Strength Index (RSI)
- 38.63
- Average Volume (3m)
- 32.21K
Important Dates
Eloxx Pharmaceuticals upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Eloxx Pharmaceuticals as a current ratio of 0.31, with Debt / Equity ratio of -8.40%
- Current Ratio
- 0.31
- Quick Ratio
- 0.31
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- 0.77
- Interest Coverage Ratio
- -6.14
Taxes
In the past 12 months, Eloxx Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Eloxx Pharmaceuticals EV to EBITDA ratio is 2.11, with an EV/FCF ratio of 1.68.
- EV to Sales
- 0.00
- EV to EBITDA
- 2.11
- EV to Free Cash Flow
- 1.68
- EV to Operating Cash Flow
- 1.68
Balance Sheet
Eloxx Pharmaceuticals has $61.96M in cash and marketable securities with $0.00 in debt, giving a net cash position of $61.96M billion.
- Cash & Marketable Securities
- $61.96M
- Total Debt
- $0.00
- Net Cash
- $61.96M
- Net Cash Per Share
- $15.35
- Tangible Book Value Per Share
- $6.84
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Eloxx Pharmaceuticals is $37.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $37.50
- Price Target Upside
- 190.70% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 6
- AI Score
- 43
